vs
科睿唯安（CLVT）与Cooper Companies (The)（COO）财务数据对比。点击上方公司名可切换其他公司
Cooper Companies (The)的季度营收约是科睿唯安的1.8倍（$1.1B vs $585.5M），Cooper Companies (The)净利率更高（7.9% vs -6.9%，领先14.8%），Cooper Companies (The)同比增速更快（4.6% vs -1.4%），Cooper Companies (The)自由现金流更多（$149.9M vs $78.9M），过去两年Cooper Companies (The)的营收复合增速更高（6.9% vs -5.1%）
科睿唯安是一家英美合资的上市分析服务企业，主要提供订阅制信息服务，覆盖文献计量、科学计量、商业与市场情报领域，同时为医药、生物科技行业提供专利、监管合规相关的竞争分析，也提供商标保护、域名与品牌保护服务，旗下Web of Science产品系列还负责计算学术期刊的影响因子。
CooperCompanies是总部位于美国加利福尼亚州圣拉蒙的全球医疗设备企业，旗下设有两大业务单元：主营隐形眼镜生产的库博光学，以及面向女性健康市场提供医疗设备、生育及基因组相关产品的库博外科。
CLVT vs COO — 直观对比
营收规模更大
COO
是对方的1.8倍
$585.5M
营收增速更快
COO
高出6.0%
-1.4%
净利率更高
COO
高出14.8%
-6.9%
自由现金流更多
COO
多$71.0M
$78.9M
两年增速更快
COO
近两年复合增速
-5.1%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $585.5M | $1.1B |
| 净利润 | $-40.2M | $84.6M |
| 毛利率 | 67.2% | 61.1% |
| 营业利润率 | 5.2% | 13.2% |
| 净利率 | -6.9% | 7.9% |
| 营收同比 | -1.4% | 4.6% |
| 净利润同比 | 61.3% | -28.0% |
| 每股收益（稀释后） | $-0.06 | $0.42 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLVTCOO
| Q1 26 | $585.5M | — | ||
| Q4 25 | $617.0M | $1.1B | ||
| Q3 25 | $623.1M | $1.1B | ||
| Q2 25 | $621.4M | $1.0B | ||
| Q1 25 | $593.7M | $964.7M | ||
| Q4 24 | $663.0M | $1.0B | ||
| Q3 24 | $622.2M | $1.0B | ||
| Q2 24 | $650.3M | $942.6M |
净利润CLVTCOO
| Q1 26 | $-40.2M | — | ||
| Q4 25 | $3.1M | $84.6M | ||
| Q3 25 | $-28.3M | $98.3M | ||
| Q2 25 | $-72.0M | $87.7M | ||
| Q1 25 | $-103.9M | $104.3M | ||
| Q4 24 | $-191.8M | $117.5M | ||
| Q3 24 | $-65.6M | $104.7M | ||
| Q2 24 | $-304.3M | $88.9M |
毛利率CLVTCOO
| Q1 26 | 67.2% | — | ||
| Q4 25 | 66.8% | 61.1% | ||
| Q3 25 | 65.0% | 65.3% | ||
| Q2 25 | 67.2% | 67.8% | ||
| Q1 25 | 65.1% | 68.4% | ||
| Q4 24 | 65.7% | 66.5% | ||
| Q3 24 | 66.2% | 66.1% | ||
| Q2 24 | 67.2% | 67.0% |
营业利润率CLVTCOO
| Q1 26 | 5.2% | — | ||
| Q4 25 | 6.7% | 13.2% | ||
| Q3 25 | 7.1% | 16.6% | ||
| Q2 25 | 1.1% | 18.4% | ||
| Q1 25 | -3.5% | 18.9% | ||
| Q4 24 | -9.4% | 19.5% | ||
| Q3 24 | 3.5% | 19.2% | ||
| Q2 24 | -36.9% | 17.2% |
净利率CLVTCOO
| Q1 26 | -6.9% | — | ||
| Q4 25 | 0.5% | 7.9% | ||
| Q3 25 | -4.5% | 9.3% | ||
| Q2 25 | -11.6% | 8.7% | ||
| Q1 25 | -17.5% | 10.8% | ||
| Q4 24 | -28.9% | 11.5% | ||
| Q3 24 | -10.5% | 10.4% | ||
| Q2 24 | -46.8% | 9.4% |
每股收益（稀释后）CLVTCOO
| Q1 26 | $-0.06 | — | ||
| Q4 25 | $0.00 | $0.42 | ||
| Q3 25 | $-0.04 | $0.49 | ||
| Q2 25 | $-0.11 | $0.44 | ||
| Q1 25 | $-0.15 | $0.52 | ||
| Q4 24 | $-0.27 | $0.59 | ||
| Q3 24 | $-0.09 | $0.52 | ||
| Q2 24 | $-0.46 | $0.44 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $110.6M |
| 总债务越低越好 | $4.3B | $2.5B |
| 股东权益账面价值 | $4.8B | $8.2B |
| 总资产 | $10.9B | $12.4B |
| 负债/权益比越低杠杆越低 | 0.89× | 0.30× |
8季度趋势，按日历期对齐
现金及短期投资CLVTCOO
| Q1 26 | — | — | ||
| Q4 25 | $329.2M | $110.6M | ||
| Q3 25 | $318.7M | $124.9M | ||
| Q2 25 | $362.6M | $116.2M | ||
| Q1 25 | $354.0M | $100.9M | ||
| Q4 24 | $295.2M | $107.6M | ||
| Q3 24 | $388.5M | $109.7M | ||
| Q2 24 | $376.4M | $112.4M |
总债务CLVTCOO
| Q1 26 | $4.3B | — | ||
| Q4 25 | $4.3B | $2.5B | ||
| Q3 25 | $4.4B | $2.4B | ||
| Q2 25 | $4.5B | $2.5B | ||
| Q1 25 | $4.5B | $2.5B | ||
| Q4 24 | $4.5B | $2.6B | ||
| Q3 24 | $4.6B | $2.6B | ||
| Q2 24 | $4.6B | $2.7B |
股东权益CLVTCOO
| Q1 26 | $4.8B | — | ||
| Q4 25 | $4.8B | $8.2B | ||
| Q3 25 | $4.9B | $8.4B | ||
| Q2 25 | $5.0B | $8.3B | ||
| Q1 25 | $5.0B | $8.1B | ||
| Q4 24 | $5.1B | $8.1B | ||
| Q3 24 | $5.5B | $7.9B | ||
| Q2 24 | $5.6B | $7.8B |
总资产CLVTCOO
| Q1 26 | $10.9B | — | ||
| Q4 25 | $11.1B | $12.4B | ||
| Q3 25 | $11.2B | $12.4B | ||
| Q2 25 | $11.4B | $12.4B | ||
| Q1 25 | $11.5B | $12.2B | ||
| Q4 24 | $11.5B | $12.3B | ||
| Q3 24 | $12.0B | $12.1B | ||
| Q2 24 | $12.1B | $12.0B |
负债/权益比CLVTCOO
| Q1 26 | 0.89× | — | ||
| Q4 25 | 0.89× | 0.30× | ||
| Q3 25 | 0.90× | 0.29× | ||
| Q2 25 | 0.90× | 0.30× | ||
| Q1 25 | 0.90× | 0.31× | ||
| Q4 24 | 0.88× | 0.32× | ||
| Q3 24 | 0.84× | 0.33× | ||
| Q2 24 | 0.83× | 0.34× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $134.7M | $247.9M |
| 自由现金流经营现金流 - 资本支出 | $78.9M | $149.9M |
| 自由现金流率自由现金流/营收 | 13.5% | 14.1% |
| 资本支出强度资本支出/营收 | 9.5% | 9.2% |
| 现金转化率经营现金流/净利润 | — | 2.93× |
| 过去12个月自由现金流最近4个季度 | $333.9M | $433.7M |
8季度趋势，按日历期对齐
经营现金流CLVTCOO
| Q1 26 | $134.7M | — | ||
| Q4 25 | $159.9M | $247.9M | ||
| Q3 25 | $181.1M | $261.4M | ||
| Q2 25 | $116.3M | $96.2M | ||
| Q1 25 | $171.2M | $190.6M | ||
| Q4 24 | $141.3M | $268.1M | ||
| Q3 24 | $202.9M | $207.5M | ||
| Q2 24 | $126.2M | $111.0M |
自由现金流CLVTCOO
| Q1 26 | $78.9M | — | ||
| Q4 25 | $89.2M | $149.9M | ||
| Q3 25 | $115.5M | $164.5M | ||
| Q2 25 | $50.3M | $18.1M | ||
| Q1 25 | $110.3M | $101.2M | ||
| Q4 24 | $59.1M | $128.1M | ||
| Q3 24 | $126.3M | $118.5M | ||
| Q2 24 | $60.3M | $36.9M |
自由现金流率CLVTCOO
| Q1 26 | 13.5% | — | ||
| Q4 25 | 14.5% | 14.1% | ||
| Q3 25 | 18.5% | 15.5% | ||
| Q2 25 | 8.1% | 1.8% | ||
| Q1 25 | 18.6% | 10.5% | ||
| Q4 24 | 8.9% | 12.6% | ||
| Q3 24 | 20.3% | 11.8% | ||
| Q2 24 | 9.3% | 3.9% |
资本支出强度CLVTCOO
| Q1 26 | 9.5% | — | ||
| Q4 25 | 11.5% | 9.2% | ||
| Q3 25 | 10.5% | 9.1% | ||
| Q2 25 | 10.6% | 7.8% | ||
| Q1 25 | 10.3% | 9.3% | ||
| Q4 24 | 12.4% | 13.7% | ||
| Q3 24 | 12.3% | 8.9% | ||
| Q2 24 | 10.1% | 7.9% |
现金转化率CLVTCOO
| Q1 26 | — | — | ||
| Q4 25 | 51.58× | 2.93× | ||
| Q3 25 | — | 2.66× | ||
| Q2 25 | — | 1.10× | ||
| Q1 25 | — | 1.83× | ||
| Q4 24 | — | 2.28× | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 1.25× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLVT
| Subscription | $397.5M | 68% |
| Re-occurring | $108.6M | 19% |
| Transactional | $79.4M | 14% |
COO
| Sphere Other | $365.0M | 34% |
| Toric And Multifocal | $344.7M | 32% |
| Office And Surgical | $214.5M | 20% |
| Fertility | $140.9M | 13% |
